Patients with HER2-overexpressing breast cancers have had more effective systemic therapy for CNS disease since the introduction of lapatinib in 2007 and specifically since the LANDSCAPE trial in 2013, which demonstrated that patients with parenchymal brain metastases could delay radiation and a substantial percentage of intracranial responses were observed [20–22]. This evidence concerns the gene ERBB2 and breast carcinoma.